Congress Pearls: Pearls of EULAR

Pearls of Congress Overview

In the Congress Pearls on-demand video series, expert faculty present succinct highlights of the latest clinical studies shown at major congresses, with critical insights into how these new data impact daily clinical practice in dermatology and rheumatology. If you have not had the opportunity to attend a major congress, or missed certain important sessions while busy at the congress, catch up by watching these easily accessible,  on-demand short Pearls videos at your own pace.

Episode Overview

In the Pearls of EULAR 2022, Prof. Gerd Burmester, Dr Philipp Sewerin, and Dr Alen Zabotti will provide their highlights from the recent EULAR 2022 Congress. These include the latest updates on current treatments and future outlooks for rheumatic diseases such as psoriatic arthritis (PsA), rheumatoid arthritis (RA), and systemic lupus erythematosus (SLE), and the implications these new clinical results will have on patient management in the clinic. These studies were presented at the EULAR 2022 Congress in Copenhagen, Denmark, and the Pearls of EULAR 2022 is divided into four exciting segments.

Faculty

Scientific Committee:

Dr Philip Sewerin
Department of Rheumatology and Hiller Research Unit for Rheumatology, Heinrich Heine University Düsseldorf, Düsseldorf, Germany

Dr Alen Zabotti
Rheumatology Unit, Department of Medicine, University of Udine, Azienda Sanitaria Universitaria Friuli Centrale, Udine, Italy 

Expert speaker:

Professor Gerd Burmester
Department of Rheumatology and Clinical Immunology, Charité – Universitätsmedizin Berlin, Humboldt University and Free University, Berlin, Germany

Part 1: The Pearls of Prof. Burmester

The advances in systemic treatments have led to improved patient outcomes for diseases such as PsA and RA, but with more answers come more questions! In this video, the faculty will discuss advances in the treatment of PsA with interleukin (IL)-23 inhibitors, looking deeper into changes in serum cytokines during treatment and 2-year safety data, before moving on the safety thread to look at the recent data of Janus kinase (JAK) inhibitors, cardiovascular risk, and what all of this may mean for the clinic.

Part 2: The Pearls of Dr Sewerin

During this congress, we saw many positive and interesting developments in the management of PsA. Are you curious as to what interesting data were presented in looking at the predictors of sustained remission and risk of haematological malignancy patients with PsA from Nordic cohorts? Or maybe how power Doppler ultrasound could be used to assess synovitis in patients with PsA? Tune in to this video to find out more, and how this could impact your clinical practice.

Part 3: The Pearls of Dr Zabotti

PsA is a heterogenous disease that involves many domains that could present simultaneously. During this video, Dr Zabotti will take you through two interesting studies looking at the involvement of these different domains, specifically looking at how machine learning can be used to identify different phenotypes of patients with PsA, and how this may predict treatment outcomes, before then looking at the burden on quality of life for patients with both psoriasis and PsA.

Part 4: Late-breaking news and Post-Congress Edition

Join us for the last video in the Pearls of EULAR 2022 video series, where all of our expert faculty join together to discuss the late-breaking abstracts and personal highlights from EULAR 2022 in our post-congress pearls. What new treatment outlooks are on the horizon for SLE? New modes of action for the treatment of PsA? And how, using ultrasound imaging, dermatologists and rheumatologists could work together to improve management and early detection of PsA in patients with psoriasis. Please tune in to find out more!